1. Home
  2. RFM vs AVTX Comparison

RFM vs AVTX Comparison

Compare RFM & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RFM
  • AVTX
  • Stock Information
  • Founded
  • RFM 2020
  • AVTX 2011
  • Country
  • RFM United States
  • AVTX United States
  • Employees
  • RFM N/A
  • AVTX N/A
  • Industry
  • RFM Finance/Investors Services
  • AVTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • RFM Finance
  • AVTX Health Care
  • Exchange
  • RFM Nasdaq
  • AVTX Nasdaq
  • Market Cap
  • RFM 92.3M
  • AVTX 88.4M
  • IPO Year
  • RFM N/A
  • AVTX 2015
  • Fundamental
  • Price
  • RFM $15.61
  • AVTX $8.18
  • Analyst Decision
  • RFM
  • AVTX Strong Buy
  • Analyst Count
  • RFM 0
  • AVTX 4
  • Target Price
  • RFM N/A
  • AVTX $33.00
  • AVG Volume (30 Days)
  • RFM 20.7K
  • AVTX 65.8K
  • Earning Date
  • RFM 01-01-0001
  • AVTX 03-28-2025
  • Dividend Yield
  • RFM 9.74%
  • AVTX N/A
  • EPS Growth
  • RFM N/A
  • AVTX N/A
  • EPS
  • RFM N/A
  • AVTX N/A
  • Revenue
  • RFM N/A
  • AVTX $820,000.00
  • Revenue This Year
  • RFM N/A
  • AVTX N/A
  • Revenue Next Year
  • RFM N/A
  • AVTX N/A
  • P/E Ratio
  • RFM N/A
  • AVTX N/A
  • Revenue Growth
  • RFM N/A
  • AVTX N/A
  • 52 Week Low
  • RFM $12.89
  • AVTX $4.17
  • 52 Week High
  • RFM $16.41
  • AVTX $34.46
  • Technical
  • Relative Strength Index (RSI)
  • RFM 65.66
  • AVTX 52.50
  • Support Level
  • RFM $15.24
  • AVTX $7.82
  • Resistance Level
  • RFM $15.60
  • AVTX $8.50
  • Average True Range (ATR)
  • RFM 0.07
  • AVTX 0.78
  • MACD
  • RFM 0.05
  • AVTX 0.20
  • Stochastic Oscillator
  • RFM 99.98
  • AVTX 73.11

About RFM RiverNorth Flexible Municipal Income Fund Inc.

RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Share on Social Networks: